Mont-Saint-Guibert (Belgium), August 30, 2023, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.
Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 310 310 1313

| Last Trade: | US$4.57 |
| Daily Change: | 0.03 0.66 |
| Daily Volume: | 111,107 |
| Market Cap: | US$196.650M |
November 13, 2025 November 13, 2025 September 23, 2025 September 02, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load